On the other hand, monoamine oxidase (MAO)-A is primarily targeted for the treatment of depression and anxiety, whereas MAO-B is targeted for AD and Parkinson’s disease, based on their specificity, which is, MAO-A prefers serotonin, and MAO-B prefers phenylethylamine and benzylamine [8]. Here, MAOA is linked to major depressive disorder.